DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION

Covalon Technologies Ltd.

TSXV:COV Stock Report

Market Cap: CA$102.2m

  • Company Overview
    • Valuation
    • Future Growth
    • Past Performance
    • Financial Health
    • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

Covalon Technologies Past Earnings Performance

Past criteria checks 5/6

Covalon Technologies has been growing earnings at an average annual rate of 45.9%, while the Biotechs industry saw earnings growing at 34.1% annually. Revenues have been growing at an average rate of 16.2% per year. Covalon Technologies's return on equity is 13.9%, and it has net margins of 12.8%.

Key information

45.90%

Earnings growth rate

45.06%

EPS growth rate

Biotechs Industry Growth51.09%
Revenue growth rate16.18%
Return on equity13.91%
Net Margin12.78%
Last Earnings Update30 Jun 2026

Recent past performance updates

Recent updates

Analysis Article • Aug 20

Covalon Technologies Ltd.'s (CVE:COV) Popularity With Investors Is Under Threat From Overpricing

TSXV:COV 1 Year Share Price vs Fair Value Explore Covalon Technologies's Fair Values from the Community and select...
Analysis Article • Feb 26

Some Shareholders Feeling Restless Over Covalon Technologies Ltd.'s (CVE:COV) P/S Ratio

It's not a stretch to say that Covalon Technologies Ltd.'s ( CVE:COV ) price-to-sales (or "P/S") ratio of 2.1x seems...
Analysis Article • Nov 17

Subdued Growth No Barrier To Covalon Technologies Ltd. (CVE:COV) With Shares Advancing 29%

Covalon Technologies Ltd. ( CVE:COV ) shares have continued their recent momentum with a 29% gain in the last month...
Analysis Article • Aug 18

Covalon Technologies Ltd.'s (CVE:COV) 25% Share Price Surge Not Quite Adding Up

Despite an already strong run, Covalon Technologies Ltd. ( CVE:COV ) shares have been powering on, with a gain of 25...
Analysis Article • Aug 10

We Think Covalon Technologies (CVE:COV) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jun 16

Optimistic Investors Push Covalon Technologies Ltd. (CVE:COV) Shares Up 83% But Growth Is Lacking

Covalon Technologies Ltd. ( CVE:COV ) shareholders would be excited to see that the share price has had a great month...
Analysis Article • May 01

Covalon Technologies (CVE:COV) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Feb 17

Covalon Technologies Ltd.'s (CVE:COV) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Covalon Technologies Ltd. ( CVE:COV ) shares have continued their recent momentum with a 25% gain in the last month...
Analysis Article • Dec 22

Insufficient Growth At Covalon Technologies Ltd. (CVE:COV) Hampers Share Price

With a price-to-sales (or "P/S") ratio of 1.2x Covalon Technologies Ltd. ( CVE:COV ) may be sending bullish signals at...
Analysis Article • Sep 02

We Think Covalon Technologies (CVE:COV) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • May 26

We Think Covalon Technologies (CVE:COV) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Apr 29

Is Covalon Technologies (CVE:COV) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Dec 29

Covalon Technologies (CVE:COV) Is Making Moderate Use Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Revenue & Expenses Breakdown

How Covalon Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSXV:COV Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 26344151
31 Mar 26332151
31 Dec 25321151
30 Sep 25332141
30 Jun 25332151
31 Mar 25344152
31 Dec 24355142
30 Sep 24313152
30 Jun 2429-1162
31 Mar 2426-3162
31 Dec 2325-5181
30 Sep 2327-4171
30 Jun 2325-6171
31 Mar 2323-7171
31 Dec 2219-9161
30 Sep 2218-9151
30 Jun 2219-4111
31 Mar 2221-2101
31 Dec 2122091
30 Sep 2120081
30 Jun 217-421
31 Mar 217-431
31 Dec 208-871
30 Sep 2014-8111
30 Jun 2026-8231
31 Mar 2027-12261
31 Dec 1935-8281
30 Sep 1934-9291
30 Jun 1934-6261
31 Mar 1935-1231
31 Dec 1828-1191
30 Sep 18272171
30 Jun 18303191
31 Mar 18281191
31 Dec 17282181
30 Sep 17272181
30 Jun 1718-1141
31 Mar 1715-1121
31 Dec 1610-391
30 Sep 167-361
30 Jun 168-261
31 Mar 167-251
31 Dec 159051
30 Sep 158-151

Quality Earnings: COV has high quality earnings.

Growing Profit Margin: COV's current net profit margins (12.8%) are higher than last year (7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: COV has become profitable over the past 5 years, growing earnings by 45.9% per year.

Accelerating Growth: COV's earnings growth over the past year (89.7%) exceeds its 5-year average (45.9% per year).

Earnings vs Industry: COV earnings growth over the past year (89.7%) exceeded the Biotechs industry 67.9%.


Return on Equity

High ROE: COV's Return on Equity (13.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/21 00:01
End of Day Share Price 2026/09/21 00:00
Earnings2026/06/30
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Covalon Technologies Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andre UddinResearch Capital Corporation

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide